Navigation Links
Heartburn Drugs May Contribute to the Problem
Date:7/7/2009

Study suggests proton pump inhibitors could aggravate acid trouble

TUESDAY, July 7 (HealthDay News) -- Drugs commonly used to treat heartburn and acid reflux may actually cause heartburn.

A new study in the July issue of Gastroenterology found that treatment with a proton pump inhibitor (PPI) actually produced heartburn, acid reflux and indigestion in healthy volunteers who took the medication for eight weeks.

Although the findings don't necessarily mean that PPIs don't have a valid place in the gastrointestinal armamentarium, they do strongly suggest that overprescribing may be causing harm, the study authors said.

"It is beyond any doubt that subjects with reflux disease benefit from and need treatment with acid suppressive drugs," said study lead author Dr. Cristina Reimer of Copenhagen University in Denmark. "But it is equally beyond doubt that PPIs are prescribed more or less uncritically for a wide variety of symptoms where the initial effect of the drug is doubtful.

"The findings in our study [indicate that] this liberal prescribing is likely to create the disease the drugs are designed to treat," she continued. "Patients who are treated on uncertain indication thus risk developing a true need for continued therapy. Our findings challenge the very liberal prescribing of these drugs, and this study should lead to careful consideration about possible changes in prescribing habits."

According to an accompanying editorial in the journal, about 5 percent of the developed world's population now uses PPIs.

And more people are using the drugs long-term, although this should only occur when a person has severe gastroesophageal reflux disease (GERD) or to prevent problems in people taking nonsteroidal anti-inflammatory medications, such as aspirin, which can be hard on the stomach, the researchers said.

But according to the study authors, about one-third of patients who take PPIs renew their prescriptions without one of these indications. And the editorial stated that the drugs are being prescribed without hard evidence that acid is involved with the problem. PPIs work by reducing acid production.

For this study, 120 healthy people were randomly assigned to receive 12 weeks of a placebo or eight weeks of Nexium (esomeprazole, 40 milligrams a day), followed by four weeks of placebo.

Forty-four percent of individuals receiving the PPI reported acid-related symptoms afterstopping the medication, compared with 15 percent in the placebo group.

The study authors speculated that the post-treatment effect comes from an acid "rebound" after the period of inhibition. If this does turn out to be the case, the process could end up causing dependency on PPIs, the researchers said.

"Patients need to be informed about the potential effects of the rebound acid hypersecretion and the symptoms it can cause when therapy is initiated," said Reimer, adding that more research into the phenomenon is needed.

"If both patients and their physicians are aware of this temporary period of time after discontinuation [that might include] aggravation or induction of acid-related symptoms, it is possible that withdrawal of therapy is easier to achieve," she added.

Blair Hains, a spokesman for AstraZeneca, which makes Nexium, said: "This study was conducted with healthy volunteers, and the authors acknowledge that they can't be sure that the conclusion can be carried over to patients who have started PPI therapy because of dyspeptic symptoms. A previous systematic review of rebound acid hypersecretion after discontinuation of PPIs concludes that there is no strong evidence for a clinically relevant increased acid production after withdrawal of PPI therapy."

More information

Visit the U.S. National Institute of Diabetes and Digestive and Kidney Diseases for more on GERD.



SOURCES: Christina Reimer, M.D., department of medical gastroenterology, Koge University Hospital, Copenhagen University, Denmark; Blair Hains, spokesman, AstraZeneca; July 2009, Gastroenterology


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Heartburn Can Be a Sign of Serious Disease
2. Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays
3. FDA Confirms No Heart Risk From Heartburn Drugs
4. AUDIO from Medialink and Prilosec OTC: Recipes for Heartburn-Friendly Super Bowl Snacking
5. First Over-The-Counter Store Brand Omeprazole Offering in U.S. Market Creates New Option for Frequent Heartburn Sufferers
6. Survey Reveals Heartburn Sufferers Experience More Heartburn During the Holidays
7. CHPA, Nielsen: OTC Heartburn Therapy Saves Nearly $800 Million Annually, Vast Majority of OTC Heartburn Consumers Satisfied
8. Plavix Plus Heartburn Drugs May Hike Heart Risk
9. Blood Thinner, Heartburn Drugs May Be Risky After Heart Attack
10. Heartburn Sufferers Find Lasting Relief With TUMS(R) Dual Action
11. Heartburn medications do not ease asthma symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... The producers of Enterprises ... businesses. , The increasingly modern world of instantaneous consumption proves very convenient for ... sources such as oil and coal, which pollutes our air, water, and soil. It ...
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of ... perfection, go out of their way to be romantic, and may exaggerate a strength ... at any online dating profile. , A recent study from Queendom.com , ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... VA (PRWEB) , ... February 12, 2016 , ... ... Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... in the life cycle of pharmaceutical products, garnering increased attention from all stakeholders ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology ... for the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards ... Executive Forum and Awards Gala on March 15, 2016 at the Westin Peachtree ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... 11, 2016 The primary goal of this ... patterns on the usage of liquid biopsy. Key information ... - Timeframe of liquid biopsy adoption amidst future ... Evs—by organization type - Sample inflow to conduct liquid ... stool, serum, and so on. - Correlation analysis of ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... and improving the lives of pets, today announced the ... the New Animal Drug Application (NADA) for Zimeta™ (dipyrone ... study (KB0120) of Zimeta for the control of pyrexia ... --> --> The ...
Breaking Medicine Technology: